Main Menu


Publications Highlights View all by category

Types of Publications

Journal Articles

Scott, A.J., Alexander, J.L., Merrifield, C.A., Cunningham, D., Jobin, C., Brown, R., Alverdy, J., O’Keefe, S.J., Gaskins, H.R., Teare, J., et al. (2019). International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut, Vol.68 (9), pp. 1624-1632.  show abstract

Phelps, D.L., Balog, J., Gildea, L.F., Bodai, Z., Savage, A., El-Bahrawy, M.A., Speller, A.V., Rosini, F., Kudo, H., McKenzie, J.S., et al. (2018). The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS). British journal of cancer, Vol.118 (10), pp. 1349-1358.

Stronach, E.A., Paul, J., Timms, K.M., Hughes, E., Brown, K., Neff, C., Perry, M., Gutin, A., El-Bahrawy, M., Steel, J.H., et al. (2018). Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. Molecular cancer research, Vol.16 (7), pp. 1103-1111.

Curry, E., Zeller, C., Masrour, N., Patten, D.K., Gallon, J., Wilhelm-Benartzi, C.S., Ghaem-Maghami, S., Bowtell, D.D. & Brown, R. (2018). Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis. Cancer research, Vol.78 (6), pp. 1383-1391.

Flanagan, J.M., Wilson, A., Koo, C., Masrour, N., Gallon, J., Loomis, E., Flower, K., Wilhelm-Benartzi, C., Hergovich, A., Cunnea, P., et al. (2017). Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. Clinical cancer research, Vol.23 (9), pp. 2213-2222.

Wilhelm-Benartzi, C.S., Mt-Isa, S., Fiorentino, F., Brown, R. & Ashby, D. (2017). Challenges and methodology in the incorporation of biomarkers in cancer clinical trials. Critical reviews in oncology/hematology, Vol.110, pp. 49-61.

Phelps, D.L., Borley, J.V., Flower, K.J., Dina, R., Darb-Esfahani, S., Braicu, I., Sehouli, J., Fotopoulou, C., Wilhelm-Benartzi, C.S., Gabra, H., et al. (2017). Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. British journal of cancer, Vol.116 (10), pp. 1287-1293.

Flower, K.J., Ghaem-Maghami, S. & Brown, R. (2017). Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?. Current cancer drug targets, Vol.18 (1).

Hollestelle, A., van der Baan, F.H., Berchuck, A., Johnatty, S.E., Aben, K.K., Agnarsson, B.A., Aittomäki, K., Alducci, E., Andrulis, I.L., Anton-Culver, H., et al. (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic oncology, Vol.141 (2), pp. 386-401.

He, Y.J., Winham, S.J., Hoskins, J.M., Glass, S., Paul, J., Brown, R., Motsinger-Reif, A. & McLeod, H.L. (2016). Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. The pharmacogenomics journal, Vol.16 (3), pp. 243-248.

Lanchbury, J., Timms, K., Reid, J., Stronach, E., Gutin, A., Krivak, T., Hennessy, B., Paul, J., Brown, R., Nix, R., et al. (2016). 3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC). Annals of oncology, Vol.27 (suppl_6).

Dória, M.L., McKenzie, J.S., Mroz, A., Phelps, D.L., Speller, A., Rosini, F., Strittmatter, N., Golf, O., Veselkov, K., Brown, R., et al. (2016). Epithelial ovarian carcinoma diagnosis by desorption electrospray ionization mass spectrometry imaging. Scientific reports, Vol.6 (1).

Bonito, N.A., Borley, J., Wilhelm-Benartzi, C.S., Ghaem-Maghami, S. & Brown, R. (2016). Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. Clinical cancer research, Vol.22 (12), pp. 3097-3104.

Flanagan, J.M., Brook, M.N., Orr, N., Tomczyk, K., Coulson, P., Fletcher, O., Jones, M.E., Schoemaker, M.J., Ashworth, A., Swerdlow, A., et al. (2015). Temporal stability and determinants of white blood cell DNA methylation in the breakthrough generations study. Cancer epidemiol biomarkers prev, Vol.24 (1), pp. 221-229.  show abstract

Flower, K.J., Shenker, N.S., El-Bahrawy, M., Goldgar, D.E., Parsons, M.T., Spurdle, A.B., Morris, J.R., Brown, R. & Flanagan, J.M. (2015). DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer. Epigenetics, Vol.10 (12), pp. 1121-1132.

Borley, J. & Brown, R. (2015). Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Annals of medicine, Vol.47 (5), pp. 359-369.

Patch, A.-., Christie, E.L., Etemadmoghadam, D., Garsed, D.W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P.J., et al. (2015). Whole–genome characterization of chemoresistant ovarian cancer. Nature, Vol.521 (7553), pp. 489-494.

Shenker, N.S., Flower, K.J., Wilhelm-Benartzi, C.S., Dai, W., Bell, E., Gore, E., El Bahrawy, M., Weaver, G., Brown, R. & Flanagan, J.M., et al. (2015). Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues. Bmc cancer, Vol.15 (1).

Curry, E., Green, I., Chapman-Rothe, N., Shamsaei, E., Kandil, S., Cherblanc, F.L., Payne, L., Bell, E., Ganesh, T., Srimongkolpithak, N., et al. (2015). Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. Clinical epigenetics, Vol.7 (1).

Charbonneau, B., Block, M.S., Bamlet, W.R., Vierkant, R.A., Kalli, K.R., Fogarty, Z., Rider, D.N., Sellers, T.A., Tworoger, S.S., Poole, E., et al. (2014). Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer res, Vol.74 (3), pp. 852-861.  show abstract

Charbonneau, B., Moysich, K.B., Kalli, K.R., Oberg, A.L., Vierkant, R.A., Fogarty, Z.C., Block, M.S., Maurer, M.J., Goergen, K.M., Fridley, B.L., et al. (2014). Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. Cancer immunology research, Vol.2 (4), pp. 332-340.

Earp, M.A., Kelemen, L.E., Magliocco, A.M., Swenerton, K.D., Chenevix-Trench, G., Lu, Y., Hein, A., Ekici, A.B., Beckmann, M.W., Fasching, P.A., et al. (2014). Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human genetics, Vol.133 (5), pp. 481-497.

Block, M.S., Charbonneau, B., Vierkant, R.A., Fogarty, Z., Bamlet, W.R., Pharoah, P.D., Georgia Chenevix-Trench, , for AOCS, , /ACS Group, , Rossing, M.A., et al. (2014). Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer. Cancer epidemiol biomarkers prev, Vol.23 (7), pp. 1421-1427.  show abstract

Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C.S. & Borley, J. (2014). Poised epigenetic states and acquired drug resistance in cancer. Nat rev cancer, Vol.14 (11), pp. 747-753.  show abstract

van der Wijst, M.G., Brown, R. & Rots, M.G. (2014). Nrf2, the master redox switch: the Achilles' heel of ovarian cancer?. Biochim biophys acta, Vol.1846 (2), pp. 494-509.  show abstract

Glasspool, R.M., Brown, R., Gore, M.E., Rustin, G.J., McNeish, I.A., Wilson, R.H., Pledge, S., Paul, J., Mackean, M., Hall, G.D., et al. (2014). A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br j cancer, Vol.110 (8), pp. 1923-1929.  show abstract

Huang, H., Benzonana, L.L., Zhao, H., Watts, H.R., Perry, N.J., Bevan, C., Brown, R. & Ma, D. (2014). Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination. Br j cancer, Vol.111 (7), pp. 1338-1349.  show abstract

Shenker, N.S., Polidoro, S., van Veldhoven, K., Sacerdote, C., Ricceri, F., Birrell, M.A., Belvisi, M.G., Brown, R., Vineis, P. & Flanagan, J.M., et al. (2013). Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum mol genet, Vol.22 (5), pp. 843-851.  show abstract

Permuth-Wey, J., Lawrenson, K., Shen, H.C., Velkova, A., Tyrer, J.P., Chen, Z., Lin, H.-., Chen, Y.A., Tsai, Y.-., Qu, X., et al. (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21 31. Nature communications, Vol.4.

Shen, H., Fridley, B.L., Song, H., Lawrenson, K., Cunningham, J.M., Ramus, S.J., Cicek, M.S., Tyrer, J., Stram, D., Larson, M.C., et al. (2013). Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature communications, Vol.4.

Zeller, C., Dai, W., Curry, E., Siddiq, A., Walley, A., Masrour, N., Kitsou-Mylona, I., Anderson, G., Ghaem-Maghami, S., Brown, R., et al. (2013). The DNA Methylomes of Serous Borderline Tumors Reveal Subgroups With Malignant- or Benign-Like Profiles. American journal of pathology, Vol.182 (3), pp. 668-677.

Cherblanc, F.L., Chapman, K.L., Brown, R. & Fuchter, M.J. (2013). Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nature chemical biology, Vol.9 (3), pp. 136-137.

Stemke-Hale, K., Shipman, K., Kitsou-Mylona, I., de Castro, D.G., Hird, V., Brown, R., Flanagan, J., Gabra, H., Mills, G.B., Agarwal, R., et al. (2013). Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. Mod pathol, Vol.26 (4), pp. 544-552.  show abstract

Pharoah, P.D., Tsai, Y.-., Ramus, S.J., Phelan, C.M., Goode, E.L., Lawrenson, K., Buckley, M., Fridley, B.L., Tyrer, J.P., Shen, H., et al. (2013). GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature genetics, Vol.45 (4), pp. 362-370.

Bojesen, S.E., Pooley, K.A., Johnatty, S.E., Beesley, J., Michailidou, K., Tyrer, J.P., Edwards, S.L., Pickett, H.A., Shen, H.C., Smart, C.E., et al. (2013). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature genetics, Vol.45 (4), pp. 371-384.

White, K.L., Vierkant, R.A., Fogarty, Z.C., Charbonneau, B., Block, M.S., Pharoah, P.D., Chenevix-Trench, G., Rossing, M.A., Cramer, D.W., Pearce, C.L., et al. (2013). Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer epidemiology biomarkers & prevention, Vol.22 (5), pp. 987-992.

Borley, J., Ghaem-Maghami, S. & Brown, R. (2013). Hypomethylation of MSX1 is associated with decreased gene expression, poor progression free survival and chemotherapy resistance in serous ovarian cancer. Bjog-an international journal of obstetrics and gynaecology, Vol.120, pp. 249-249.

Shenker, N.S., Ueland, P.M., Polidoro, S., van Veldhoven, K., Ricceri, F., Brown, R., Flanagan, J.M. & Vineis, P. (2013). DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology, Vol.24 (5), pp. 712-716.  show abstract

Johnatty, S., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M.H., Henderson, M.J., Russell, A.J., Hedditch, E.L., Emmanuel, C., et al. (2013). ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic oncology, Vol.131 (1), pp. 8-14.

Flanagan, J.M., Wilhelm-Benartzi, C.S., Metcalf, M., Kaye, S.B. & Brown, R. (2013). Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. Ann oncol, Vol.24 (11), pp. 2813-2818.  show abstract

Sriraksa, R., Zeller, C., Dai, W., Siddiq, A., Walley, A.J., Limpaiboon, T. & Brown, R. (2013). Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer prev res (phila), Vol.6 (12), pp. 1348-1355.  show abstract

Cherblanc, F.L., Chapman, K.L., Reid, J., Borg, A.J., Sundriyal, S., Alcazar-Fuoli, L., Bignell, E., Demetriades, M., Schofield, C.J., DiMaggio, P.A., et al. (2013). On the histone lysine methyltransferase activity of fungal metabolite chaetocin. J med chem, Vol.56 (21), pp. 8616-8625.  show abstract

Dai, W., Zeller, C., Masrour, N., Siddiqui, N., Paul, J. & Brown, R. (2013). Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Clin cancer res, Vol.19 (20), pp. 5788-5797.  show abstract

McWhinney-Glass, S., Winham, S.J., Hertz, D.L., Yen Revollo, J., Paul, J., He, Y., Brown, R., Motsinger-Reif, A.A., McLeod, H.L. & Scottish Gynaecological Clinical Trials Group, , et al. (2013). Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin cancer res, Vol.19 (20), pp. 5769-5776.  show abstract

Wilhelm-Benartzi, C.S., Koestler, D.C., Karagas, M.R., Flanagan, J.M., Christensen, B.C., Kelsey, K.T., Marsit, C.J., Houseman, E.A. & Brown, R. (2013). Review of processing and analysis methods for DNA methylation array data. Br j cancer, Vol.109 (6), pp. 1394-1402.  show abstract

Chapman-Rothe, N., Curry, E., Zeller, C., Liber, D., Stronach, E., Gabra, H., Ghaem-Maghami, S. & Brown, R. (2013). Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene, Vol.32 (38), pp. 4586-4592.  show abstract

Hall, J.A. & Brown, R. (2013). Developing translational research infrastructure and capabilities associated with cancer clinical trials. Expert reviews in molecular medicine, Vol.15.

Brennan, K., Garcia-Closas, M., Orr, N., Fletcher, O., Jones, M., Ashworth, A., Swerdlow, A., Thorne, H., KConFab Investigators, , Riboli, E., et al. (2012). Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer res, Vol.72 (9), pp. 2304-2313.  show abstract

Cherblanc, F., Chapman-Rothe, N., Brown, R. & Fuchter, M.J. (2012). Current limitations and future opportunities for epigenetic therapies. Future med chem, Vol.4 (4), pp. 425-446.  show abstract

Thathia, S.H., Ferguson, S., Gautrey, H.E., van Otterdijk, S.D., Hili, M., Rand, V., Moorman, A.V., Meyer, S., Brown, R. & Strathdee, G., et al. (2012). Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica-the hematology journal, Vol.97 (3), pp. 371-378.

Brown, R., Kerr, K., Haoudi, A. & Darzi, A. (2012). Tackling cancer burden in the Middle East: Qatar as an example. Lancet oncol, Vol.13 (11), pp. e501-e508.  show abstract

Cosentino, L., Masrour, N., Burns, J., Fang, W., Brown, R., Burns, P. & Pors, K. (2012). Abstract 4088: Cotreatment with decitabine and paclitaxel is affected by the re-expression of drug-metabolising enzymes. Molecular and cellular biology, .

Zeller, C., Dai, W., Steele, N.L., Siddiq, A., Walley, A.J., Wilhelm-Benartzi, C.S., Rizzo, S., van der Zee, A., Plumb, J.A. & Brown, R., et al. (2012). Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene, Vol.31 (42), pp. 4567-4576.  show abstract

Borley, J., Wilhelm-Benartzi, C., Brown, R. & Ghaem-Maghami, S. (2012). Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. British journal of cancer, Vol.107 (7), pp. 1069-1074.

Pharoah, P.D., Palmieri, R.T., Ramus, S.J., Gayther, S.A., Andrulis, I.L., Anton-Culver, H., Antonenkova, N., Antoniou, A.C., Goldgar, D., BCFR Investigators, , et al. (2011). The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin cancer res, Vol.17 (11), pp. 3742-3750.  show abstract

Stronach, E.A., Alfraidi, A., Rama, N., Datler, C., Studd, J.B., Agarwal, R., Guney, T.G., Gourley, C., Hennessy, B.T., Mills, G.B., et al. (2011). HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer res, Vol.71 (13), pp. 4412-4422.  show abstract

Rizzo, S., Hersey, J.M., Mellor, P., Dai, W., Santos-Silva, A., Liber, D., Luk, L., Titley, I., Carden, C.P., Box, G., et al. (2011). Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2. Mol cancer ther, Vol.10 (2), pp. 325-335.  show abstract

Steele, N.L., Plumb, J.A., Vidal, L., Tjørnelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R., de Bono, J.S. & Evans, T.R., et al. (2011). Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer chemother pharmacol, Vol.67 (6), pp. 1273-1279.  show abstract

Goode, E.L., Chenevix-Trench, G., Hartmann, L.C., Fridley, B.L., Kalli, K.R., Vierkant, R.A., Larson, M.C., White, K.L., Keeney, G.L., Oberg, T.N., et al. (2011). Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. Cancer epidemiology biomarkers & prevention, Vol.20 (8), pp. 1638-1648.

Sriraksa, R., Zeller, C., El-Bahrawy, M.A., Dai, W., Daduang, J., Jearanaikoon, P., Chau-in, S., Brown, R. & Limpaiboon, T. (2011). CpG-island methylation study of liver fluke-related cholangiocarcinoma. Brit j cancer, Vol.104 (8), pp. 1313-1318.  show abstract

Dai, W., Teodoridis, J.M., Zeller, C., Graham, J., Hersey, J., Flanagan, J.M., Stronach, E., Millan, D.W., Siddiqui, N., Paul, J., et al. (2011). Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin cancer res, Vol.17 (12), pp. 4052-4062.  show abstract

Huang, R.S., Johnatty, S.E., Gamazon, E.R., Im, H.K., Ziliak, D., Duan, S., Zhang, W., Kistner, E.O., Chen, P., Beesley, J., et al. (2011). Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. Clinical cancer research, Vol.17 (16), pp. 5490-5500.

Amankwah, E.K., Wang, Q.G., Schildkraut, J.M., Tsai, Y.Y., Ramus, S.J., Fridley, B.L., Beesley, J., Johnatty, S.E., Webb, P.M., Chenevix-Trench, G., et al. (2011). Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. Plos one, Vol.6 (5),  show abstract

Chapman-Rothe, N. & Brown, R. (2011). Prospects for epigenetic compounds in the treatment of autoimmune disease. Adv exp med biol, Vol.711, pp. 150-161.  show abstract

Paige, A.J., Zucknick, M., Janczar, S., Paul, J., Mein, C.A., Taylor, K.J., Stewart, M., Gourley, C., Richardson, S., Perren, T., et al. (2010). WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. Eur j cancer, Vol.46 (4), pp. 818-825.  show abstract

Carden, C.P., Thavasu, P., Reid, A., Miranda, S., Crespo, M., Brown, R., Agarwal, R., Attard, G., de Bono, J.S., Kaye, S.B., et al. (2010). Correlation of elevated phosphorylated / total AKT ratio, chemoresistance and survival in ovarian cancer ascites samples. Cancer research, Vol.70.

Strathdee, G., Ferguson, S., Sim, A. & Brown, R. (2010). DNA methylation does not regulate JUNB expression in CML: Comment on "Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia" by Hoshino et al [Leuk Res 33 (2009) 1361-1366]. Leukemia res, Vol.34 (5), pp. 685-686.

Zeller, C. & Brown, R. (2010). Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. Ther adv med oncol, Vol.2 (5), pp. 319-329.  show abstract

Bolton, E.L., Tyrer, J., Song, H., Ramus, S.J., Notaridou, M., Jones, C., Sher, T., Gentry-Maharaj, A., Wozniak, E., Tsai, Y.Y., et al. (2010). Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat genet, Vol.42 (10), pp. 880-+.  show abstract

Scott, L.C., Evans, T.R., Cassidy, J., Harden, S., Paul, J., Ullah, R., O'Brien, V. & Brown, R. (2009). Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br j cancer, Vol.101 (3), pp. 410-417.  show abstract

Graham, J.S., Kaye, S.B. & Brown, R. (2009). The promises and pitfalls of epigenetic therapies in solid tumours. Eur j cancer, Vol.45 (7), pp. 1129-1136.  show abstract

Steele, N., Finn, P., Brown, R. & Plumb, J.A. (2009). Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br j cancer, Vol.100 (5), pp. 758-763.  show abstract

Huang, Y.W., Jansen, R.A., Fabbri, E., Potter, D., Liyanarachchi, S., Chan, M.W., Liu, J.C., Crijns, A.P., Brown, R., Nephew, K.P., et al. (2009). Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol rep, Vol.22 (4), pp. 853-861.  show abstract

van Es, M.A., Veldink, J.H., Saris, C.G., Blauw, H.M., van Vught, P.W., Birve, A., Lemmens, R., Schelhaas, H.J., Groen, E.J., Huisman, M.H., et al. (2009). Genome-wide association study identifies 19p13 3 (UNC13A) and 9p21 2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nature genetics, Vol.41 (10), pp. 1083-1087.

Chapman-Rothe, N. & Brown, R. (2009). Approaches to target the genome and its epigenome in cancer. Future med chem, Vol.1 (8), pp. 1481-1495.  show abstract

Steele, N.L., Plumb, J.A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., Ooi, C.E., Buhl-Jensen, P., Brown, R., Evans, T.R., et al. (2008). A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin cancer res, Vol.14 (3), pp. 804-810.  show abstract

Johnatty, S.E., Beesley, J., Paul, J., Fereday, S., Spurdle, A.B., Webb, P.M., Byth, K., Marsh, S., McLeod, H., Harnett, P.R., et al. (2008). ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin cancer res, Vol.14 (17), pp. 5594-5601.  show abstract

Marsh, S., Paul, J., McLeod, H.L. & Brown, R. (2008). Ethnic considerations in pharmacogenetic studies - In reply. J clin oncol, Vol.26 (10), pp. 1767-1768.

Dai, W., Teodoridis, J.M., Graham, J., Zeller, C., Huang, T.H., Yan, P., Vass, J.K., Brown, R. & Paul, J. (2008). Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. Bmc bioinformatics, Vol.9, p. 337.  show abstract

Paul, J., Marsh, S., McLeod, H.L. & Brown, R. (2008). No evidence for taxane/platinum pharmacogenetic markers: Just lack of power? Reply. J clin oncol, Vol.26 (11), pp. 1904-1905.

Paige, A.J. & Brown, R. (2008). Pharmaco(epi)genomics in ovarian cancer. Pharmacogenomics, Vol.9 (12), pp. 1825-1834.  show abstract

Teodoridis, J.M., Hardie, C. & Brown, R. (2008). CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer lett, Vol.268 (2), pp. 177-186.  show abstract

Strathdee, G., Holyoake, T.L., Sim, A., Parker, A., Oscier, D.G., Melo, J.V., Meyer, S., Eden, T., Dickinson, A.M., Mountford, J.C., et al. (2007). Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin cancer res, Vol.13 (17), pp. 5048-5055.  show abstract

Strathdee, G., Sim, A., Soutar, R., Holyoake, T.L. & Brown, R. (2007). HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis, Vol.28 (2), pp. 299-309.  show abstract

Hall, J.A., Brown, R. & Paul, J. (2007). An exploration into study design for biomarker identification: issues and recommendations. Cancer genomics proteomics, Vol.4 (3), pp. 111-119.  show abstract

Epping, M.T., Wang, L., Plumb, J.A., Lieb, M., Gronemeyer, H., Brown, R. & Bernards, R. (2007). A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. P natl acad sci usa, Vol.104 (45), pp. 17777-17782.  show abstract

Brown, R. & Glasspool, R. (2007). Epigenetic modulation of resistance to chemotherapy?. Ann oncol, Vol.18 (9), pp. 1429-1430.

Marsh, S., Paul, J., King, C.R., Gifford, G., McLeod, H.L. & Brown, R. (2007). Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer. J clin oncol, Vol.25 (29), pp. 4528-4535.  show abstract

Robinson, H.M., Black, E.J., Brown, R. & Gillespie, D.A. (2007). DNA mismatch repair and Chk1-dependent centrosome amplification in response to DNA alkylation damage. Cell cycle, Vol.6 (8), pp. 982-992.  show abstract

Robinson, H.M., Bratlie-Thoresen, S., Brown, R. & Gillespie, D.A. (2007). Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193. Cell cycle, Vol.6 (10), pp. 1265-1267.

Ordway, J.M., Budiman, M.A., Korshunova, Y., Maloney, R.K., Bedell, J.A., Citek, R.W., Bacher, B., Peterson, S., Rohlfing, T., Hall, J., et al. (2007). Identification of Novel High-Frequency DNA Methylation Changes in Breast Cancer. Plos one, Vol.2 (12),  show abstract

de Graeff, P., Hall, J., Crijns, A.P., de Bock, G.H., Paul, J., ten Hoor, K.A., de Jong, S., Hollema, H., Bartlett, J.M., Brown, R., et al. (2007). The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer - Reply. Brit j cancer, Vol.96 (10), pp. 1623-1624.

Marsh, S., King, C.R., McLeod, H.L., Paul, J., Gifford, G. & Brown, R. (2006). ABCB1 2677G > T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin cancer res, Vol.12 (13), pp. 4127-4127.

Wei, S.H., Balch, C., Paik, H.H., Kim, Y.S., Baldwin, R.L., Liyanarachchi, S., Li, L., Wang, Z.L., Wan, J.C., Davuluri, R.V., et al. (2006). Prognostic DNA methylation biomarkers in ovarian cancer. Clin cancer res, Vol.12 (9), pp. 2788-2794.  show abstract

O'Brien, V. & Brown, R. (2006). Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis, Vol.27 (4), pp. 682-692.  show abstract

de Graeff, P., Hall, J., Crijns, A.P., de Bock, G.H., Paul, J., Oien, K.A., ten Hoor, K.A., de Jong, S., Hollema, H., Bartlett, J.M., et al. (2006). Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Brit j cancer, Vol.95 (5), pp. 627-633.  show abstract

Strathdee, G., Sim, A., Parker, A., Oscier, D. & Brown, R. (2006). Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia, Vol.20 (7), pp. 1326-1329.

Smith, L.V., Parenty, A.D., Guthrie, K.M., Plumb, J., Brown, R. & Cronin, L. (2006). Dihydroimidazophenanthridinium (DIP)-based DNA binding agents with tuneable structures and biological activity. Chembiochem, Vol.7 (11), pp. 1757-1763.  show abstract

Giotopoulos, G., McCormick, C., Cole, C., Zanker, A., Jawad, M., Brown, R. & Plumb, M. (2006). DNA methylation during mouse hemopoietic differentiation and radiation-induced leukemia. Exp hematol, Vol.34 (11), pp. 1462-1470.  show abstract

Lindsey, J.C., Lusher, M.E., Strathdee, G., Brown, R., Gilbertson, R.J., Bailey, S., Ellison, D.W. & Clifford, S.C. (2006). Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int j cancer, Vol.118 (2), pp. 346-352.  show abstract

Glasspool, R.M., Teodoridis, J.M. & Brown, R. (2006). Epigenetics as a mechanism driving polygenic clinical drug resistance. Br j cancer, Vol.94 (8), pp. 1087-1092.  show abstract

Robinson, H.M., Jones, R., Walker, M., Zachos, G., Brown, R., Cassidy, J. & Gillespie, D.A. (2006). Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene, Vol.25 (39), pp. 5359-5369.  show abstract

Teodoridis, J.M., Hall, J., Marsh, S., Kannall, H.D., Smyth, C., Curto, J., Siddiqui, N., Gabra, H., McLeod, H.L., Strathdee, G., et al. (2005). CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer res, Vol.65 (19), pp. 8961-8967.  show abstract

Steele, N., Vidal, L., Plumb, J., Attard, G., Rasmussen, A., Buhl-Jensen, P., Brown, R., Blagden, S., Evans, J. & de Bono, J., et al. (2005). A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours. Journal of clinical oncology, Vol.23 (16), pp. 200S-200S.

Strathdee, G., Vass, J.K., Oien, K.A., Siddiqui, N., Curto-Garcia, J. & Brown, R. (2005). Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol oncol, Vol.97 (3), pp. 898-903.  show abstract

Gallagher, W.M., Bergin, O.E., Rafferty, M., Kelly, Z.D., Nolan, I.M., Fox, E.J., Culhane, A.C., McArdle, L., Fraga, M.F., Hughes, L., et al. (2005). Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis, Vol.26 (11), pp. 1856-1867.  show abstract

Parenty, A.D., Smith, L.V., Guthrie, K.M., Long, D.-., Plumb, J., Brown, R. & Cronin, L. (2005). Highly stable phenanthridinium frameworks as a new class of tunable DNA binding agents with cytotoxic properties. J med chem, Vol.48 (14), pp. 4504-4506.  show abstract

Chan, M.W., Wei, S.H., Wen, P., Wang, Z.L., Matei, D.E., Liu, J.C., Liyanarachchi, S., Brown, R., Nephew, K.P., Yan, P.S., et al. (2005). Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin cancer res, Vol.11 (20), pp. 7376-7383.  show abstract

Lyko, F. & Brown, R. (2005). DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J natl cancer i, Vol.97 (20), pp. 1498-1506.  show abstract

Pors, K., Plumb, J.A., Brown, R., Teesdale-Spittle, P., Searcey, M., Smith, P.J. & Patterson, L.H. (2005). Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells. J med chem, Vol.48 (21), pp. 6690-6695.  show abstract

Gifford, G., Paul, J., Vasey, P.A., Kaye, S.B., Brown, R. & Scottish Gynaecological Clinical, (2004). The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin cancer res, Vol.10 (13), pp. 4420-4426.  show abstract

Morley, S., MacDonald, G., Kirn, D., Kaye, S., Brown, R. & Soutar, D. (2004). The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin cancer res, Vol.10 (13), pp. 4357-4362.  show abstract

Barvaux, V.A., Ranson, M., Brown, R., McElhinney, R.S., McMurry, T.B. & Margison, G.P. (2004). Dual repair modulation reverses Temozolomide resistance in vitro. Mol cancer ther, Vol.3 (2), pp. 123-127.  show abstract

Strathdee, G., Davies, B.R., Vass, J.K., Siddiqui, N. & Brown, R. (2004). Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis, Vol.25 (5), pp. 693-701.  show abstract

Brown, R. & Plumb, J.A. (2004). Demethylation of DNA by decitabine in cancer chemotherapy. Expert rev anticancer ther, Vol.4 (4), pp. 501-510.  show abstract

Teodoridis, J.M., Strathdee, G. & Brown, R. (2004). Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug resist updat, Vol.7 (4-5), pp. 267-278.  show abstract

Strathdee, G. & Brown, R. (2004). Bioscience 2004. Pharmacogenomics, Vol.5 (7), pp. 775-778.

Batch, C., Huang, T.H., Brown, R. & Nephew, K.P. (2004). The epigenetics of ovarian cancer drug resistance and resensitization. Am j obstet gynecol, Vol.191 (5), pp. 1552-1572.  show abstract

Strathdee, G., Sim, A. & Brown, R. (2004). Control of gene expression by CpG island methylation in normal cells. Biochem soc trans, Vol.32 (Pt 6), pp. 913-915.  show abstract

Teodoridis, J.M., Strathdee, G., Plumb, J.A. & Brown, R. (2004). CpG-island methylation and epigenetic control of resistance to chemotherapy. Biochem soc trans, Vol.32 (Pt 6), pp. 916-917.  show abstract

Plumb, J.A., Steele, N., Finn, P.W. & Brown, R. (2004). Epigenetic approaches to cancer therapy. Biochem soc trans, Vol.32 (Pt 6), pp. 1095-1097.  show abstract

Lee, C., Appleton, K., Plumb, J., Kaye, S., Cruickshank, C., Twelves, C., Vasey, P., Judson, I., Brown, R. & Mackay, H., et al. (2004). A phase I trial of the DNA-hypomethylating agent 5-Aza-2'-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid tumours. J clin oncol, Vol.22 (14_suppl), p. 2005.  show abstract

Hall, J., Paul, J. & Brown, R. (2004). Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert rev mol med, Vol.6 (12), pp. 1-20.  show abstract

Gifford, G. & Brown, R. (2004). Microsatellite instability: theory and methods. Methods mol med, Vol.97, pp. 237-250.

Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J., La Thangue, N.B. & Brown, R. (2003). Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol cancer ther, Vol.2 (8), pp. 721-728.  show abstract

Kim, Y.T., Ganly, I., Brown, R. & Stuart, D. (2003). Acquired resistance to cytolysis of the E1B-attenuated adenovirus, dl1520, in ovarian tumour cell lines. Cancer gene ther, Vol.10 (8), pp. 589-590.

Mac Partlin, M., Homer, E., Robinson, H., McCormick, C.J., Crouch, D.H., Durant, S.T., Matheson, E.C., Hall, A.G., Gillespie, D.A. & Brown, R., et al. (2003). Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX. Oncogene, Vol.22 (6), pp. 819-825.  show abstract

Song, J.S., Kim, S.B., Lee, Y.H., Lee, K.W., Jung, H.H., Kim, M.H., Kim, K.T., Brown, R. & Kim, Y.T. (2002). Adenovirus-mediated antisense expression of telomerase template RNA induces apoptosis in lung cancer cells. J microbiol biotechn, Vol.12 (1), pp. 89-95.  show abstract

Strathdee, G. & Brown, R. (2002). Aberrant DNA methylation in cancer: potential clinical interventions. Expert rev mol med, Vol.4 (4), pp. 1-17.  show abstract

Strathdee, G. & Brown, R. (2002). Epigenetic cancer therapies: DNA methyltransferase inhibitors. Expert opin investig drugs, Vol.11 (6), pp. 747-754.  show abstract

Wei, S.H., Chen, C.M., Strathdee, G., Harnsomburana, J., Shyu, C.R., Rahmatpanah, F., Shi, H.D., Ng, S.W., Yan, P.S., Nephew, K.P., et al. (2002). Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin cancer res, Vol.8 (7), pp. 2246-2252.  show abstract

Brown, R. & Strathdee, G. (2002). Epigenomics and epigenetic therapy of cancer. Trends mol med, Vol.8 (4 Suppl), pp. S43-S48.  show abstract

Strathdee, G., Appleton, K., Illand, M., Millan, D.W., Sargent, J., Paul, J. & Brown, R. (2001). Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am j pathol, Vol.158 (3), pp. 1121-1127.  show abstract

Ganly, I., Kim, Y.T., Hann, B., Balmain, A. & Brown, R. (2001). Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. Gene ther, Vol.8 (5), pp. 369-375.  show abstract

Strathdee, G., Sansom, O.J., Sim, A., Clarke, A.R. & Brown, R. (2001). A role for mismatch repair in control of DNA ploidy following DNA damage. Oncogene, Vol.20 (15), pp. 1923-1927.  show abstract

Brown, R., Smith, W.E. & Graham, D. (2001). Synthesis of a benzotriazole phosphoramidite for attachment of oligonucleotides to metal surfaces. Tetrahedron lett, Vol.42 (11), pp. 2197-2200.  show abstract

Stuart, D., Khan, Q.A., Brown, R. & Dipple, A. (2001). Hydrocarbon carcinogens induce p53 activity in normal mouse tissue. Cancer lett, Vol.173 (2), pp. 111-114.  show abstract

Hirst, G.L. & Brown, R. (2001). Detection of the Replication Error Phenotype in Ovarian Cancer-PCR Analysis of Microsatellite Instability. Methods mol med, Vol.39, pp. 375-382.  show abstract

Mackay, H.J., Cameron, D., Rahilly, M., Mackean, M.J., Paul, J., Kaye, S.B. & Brown, R. (2000). Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J clin oncol, Vol.18 (1), pp. 87-93.  show abstract

Ganly, I., Soutar, D.S., Brown, R. & Kaye, S.B. (2000). p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br j cancer, Vol.82 (2), pp. 392-398.  show abstract

Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. & Brown, R. (2000). Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer res, Vol.60 (21), pp. 6039-6044.  show abstract

Heise, C., Ganly, I., Kim, Y.T., Sampson-Johannes, A., Brown, R. & Kirn, D. (2000). Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene ther, Vol.7 (22), pp. 1925-1929.  show abstract

Moreland, N.J., Illand, M., Kim, Y.T., Paul, J. & Brown, R. (1999). Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer res, Vol.59 (9), pp. 2102-2106.  show abstract

Gallagher, W.M. & Brown, R. (1999). p53-oriented cancer therapies: Current progress. Ann oncol, Vol.10 (2), pp. 139-150.  show abstract

Colella, G., Marchini, S., D'Incalci, M.D., Brown, R. & Broggini, M. (1999). Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Brit j cancer, Vol.80 (3-4), pp. 338-343.  show abstract

Strathdee, G., MacKean, M.J., Illand, M. & Brown, R. (1999). A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene, Vol.18 (14), pp. 2335-2341.  show abstract

Durant, S.T., Morris, M.M., Illand, M., McKay, H.J., McCormick, C., Hirst, G.L., Borts, R.H. & Brown, R. (1999). Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr biol, Vol.9 (1), pp. 51-54.  show abstract

Links, M. & Brown, R. (1999). Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert rev mol med, Vol.1999, pp. 1-21.  show abstract

Jones, N.A., Turner, J., McIlwrath, A.J., Brown, R. & Dive, C. (1998). Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53. Mol pharmacol, Vol.53 (5), pp. 819-826.  show abstract

McDonald, A.C. & Brown, R. (1998). Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br j cancer, Vol.78 (6), pp. 745-751.  show abstract

Veldhoen, N., Stewart, J., Brown, R. & Milner, J. (1998). Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene, Vol.16 (2), pp. 249-255.  show abstract

Yamada, M., ORegan, E., Brown, R. & Karran, P. (1997). Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic acids res, Vol.25 (3), pp. 491-495.  show abstract

Brown, R., Hirst, G.L., Gallagher, W.M., McIlwrath, A.J., Margison, G.P., van der Zee, A.G. & Anthoney, D.A. (1997). hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, Vol.15 (1), pp. 45-52.  show abstract

Gallagher, W.M., Cairney, M., Schott, B., Roninson, I.B. & Brown, R. (1997). Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene, Vol.14 (2), pp. 185-193.  show abstract

Vasey, P.A., Jones, N.A., Jenkins, S., Dive, C. & Brown, R. (1996). Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol pharmacol, Vol.50 (6), pp. 1536-1540.  show abstract

Anthoney, D.A., McIlwrath, A.J., Gallagher, W.M., Edlin, A.R. & Brown, R. (1996). Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer res, Vol.56 (6), pp. 1374-1381.  show abstract

Drummond, J.T., Anthoney, A., Brown, R. & Modrich, P. (1996). Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line. J biol chem, Vol.271 (33), pp. 19645-19648.  show abstract

McIlwrath, A.J., Brunton, V.G. & Brown, R. (1996). Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer chemother pharmacol, Vol.37 (5), pp. 423-428.  show abstract

Murphy, D.S., Hoare, S.F., Going, J.J., Mallon, E.E., George, W.D., Kaye, S.B., Brown, R., Black, D.M. & Keith, W.N. (1995). Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J natl cancer inst, Vol.87 (22), pp. 1694-1704.  show abstract

Murphy, D.S., McHardy, P., Coutts, J., Mallon, E.A., George, W.D., Kaye, S.B., Brown, R. & Keith, W.N. (1995). Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int j cancer, Vol.64 (1), pp. 18-26.  show abstract

McLeod, H.L., Douglas, F., Oates, M., Symonds, R.P., Prakash, D., van der Zee, A.G., Kaye, S.B., Brown, R. & Keith, W.N. (1994). Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int j cancer, Vol.59 (5), pp. 607-611.  show abstract




Morrison, J., Bissett, D., Stephens, I., McKay, K., Brown, R., Graham, M., Fichtingerschepman, A. & Kerr, D. (1993). The isolation and identification of cis-diamminedichloroplatinum (ii)-DNA adducts by anion-exchange HPLC and inductively coupled plasma mass-spectrometry. Int j oncol, Vol.2 (1), pp. 33-37.  show abstract

Bissett, D., McLaughlin, K., Kelland, L.R. & Brown, R. (1993). Cisplatin-DNA damage recognition proteins in human tumour extracts. Br j cancer, Vol.67 (4), pp. 742-748.  show abstract

Brown, R. (1993). p53: a target for new anticancer drugs or a target for old drugs?. Ann oncol, Vol.4 (8), pp. 623-629.

Coutts, J., Plumb, J.A., Brown, R. & Keith, W.N. (1993). Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br j cancer, Vol.68 (4), pp. 793-800.  show abstract

McLaughlin, K., Coren, G., Masters, J. & Brown, R. (1993). Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines. Int j cancer, Vol.53 (4), pp. 662-666.  show abstract

Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtĕsek, B. & Kaye, S.B. (1993). Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int j cancer, Vol.55 (4), pp. 678-684.  show abstract

Keith, W.N., Douglas, F., Wishart, G.C., McCallum, H.M., George, W.D., Kaye, S.B. & Brown, R. (1993). Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur j cancer, Vol.29A (10), pp. 1469-1475.  show abstract


Keith, W.N., Tan, K.B. & Brown, R. (1992). Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue. Genes chromosomes cancer, Vol.4 (2), pp. 169-175.  show abstract

Clugston, C.K., McLaughlin, K., Kenny, M.K. & Brown, R. (1992). Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II). Cancer res, Vol.52 (22), pp. 6375-6379.  show abstract

Brown, R. (1991). Gene amplification and drug resistance. J pathol, Vol.163 (4), pp. 287-292.

Keith, W.N. & Brown, R. (1991). Carcinogenesis and the response of tumours to anticancer drugs. Anticancer res, Vol.11 (5), pp. 1739-1743.  show abstract

McLaughlin, K., Stephens, I., McMahon, N. & Brown, R. (1991). Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line. Cancer res, Vol.51 (8), pp. 2242-2245.  show abstract

Keith, W.N., Mee, P.J. & Brown, R. (1990). Response of mouse skin tumors to doxorubicin is dependent on carcinogen exposure. Cancer res, Vol.50 (21), pp. 6841-6847.  show abstract

Keith, W.N., Stallard, S. & Brown, R. (1990). Expression of mdr1 and gst-pi in human breast tumours: comparison to in vitro chemosensitivity. Br j cancer, Vol.61 (5), pp. 712-716.  show abstract

Keith, W.N., Brown, R. & Pragnell, I.B. (1990). Retrovirus mediated transfer and expression of GM-CSF in haematopoietic cells. Br j cancer, Vol.62 (3), pp. 388-394.  show abstract

Mee, P.J. & Brown, R. (1990). Construction and hormone regulation of a novel retroviral vector. Gene, Vol.88 (2), pp. 289-292.  show abstract



Tutt, A., Tovey, H., Cheang, M., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and 2 pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial 3 4. Nature medicine, .


Gallon, J., Loomis, E., Martin, N., Flanagan, J. & Brown, R. (2018). Abstract 4326: The chromatin context and consequence of cisplatin-adduct DNA damage, Presented at Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL, Molecular and Cellular Biology / Genetics, .

Lewis, H., Brown, R., Kindinger, L., Lee, Y., Bennett, P., Takats, Z. & MacIntyre, D. (2018). Rapid mucosal metabolome profiling by desorption electrospray ionization mass spectrometry for prediction of preterm prelabour rupture of membranes, BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol.125 (8), p.E33.

Martyn, M., Liu, X., Wilhelm-Benartzi, C., Brown, R. & Ashby, D. (2017). Issues with over-fitting in predictive models produced for stratified medicine: a case study on an ovarian cancer trial, TRIALS, Vol.18.

Hoppe, M.M., Tan, D.S., Lim, D.G., Karnezis, A., Huntsman, D., Steel, J., Liu, X., Paul, J., Lewsley, L.-., Siddiqui, N., et al. (2017). Abstract B04: RAD51 expression as a biomarker of homologous recombination deficiency in ovarian cancer, Presented at Abstracts: AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; January 4-7, 2017; San Diego, CA, New Technology and Bioinformatics, .

Brown, R., Kandil, S., Sundriyal, S. & Fuchter, M. (2016). Synergy in reversing platinum resistance by combined inhibition of EZH2 and EHMT1/2, European Journal of Cancer, Vol.69, p.S74.

SHENKER, N.S., Flower, K.J., Wilhelm-Benartzi, C., Dai, W., Bell, E., El Bahrawy, M., Weaver, G., Flanagan, J.M. & Brown, R. (2015). Abstract 1063: Transcriptional implications of intragenic DNA methylation in the estrogen receptor alpha gene in breast cancer cells and tissues, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Molecular and Cellular Biology, .

Brown, R., Timms, K., Paul, J., Hughes, E., El-Bahrawy, M., Steel, J.H., Kalva, S., Liu, X., Wang, Y., Rama, N.R., et al. (2015). Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC)., Journal of Clinical Oncology, Vol.33 (15_suppl), p.5576.

Brown, R., Fuchter, M., Curry, E., Green, I., Kandil, S., Cherblanc, F., Payne, L., Chapman-Rothe, N., Shamsaei, E., Srimongkolpithak, N., et al. (2014). Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells, EUROPEAN JOURNAL OF CANCER, Vol.50, pp.179-180.

Polidoro, S., Shenker, N., van Veldhoven, K., Sacerdote, C., Ricceri, F., Critelli, R., Brown, R., Vineis, P. & Flanagan, J.M. (2012). Epigenome-wide Association Study in the European Prospective Investigation Into Cancer and Nutrition (EPIC-Turin) Identifies Novel Genes Associated With Smoking, EUROPEAN JOURNAL OF CANCER, Vol.48, pp.S124-S125.



Strathdee, G., Holyoake, T.L., Sim, A., Parker, A., Oscier, D.G., Melo, J.V., Meyer, S., Eden, T., Dickinson, A.M., Soutar, R., et al. (2007). HOX genes are a major target for epigenetic mis-regulation in adult and childhood leukaemia, Presented at 47th Annual Scientific Meeting of the British-Society-for-Haematology, Bournemouth, ENGLAND. BRITISH JOURNAL OF HAEMATOLOGY, Vol.137, p.81.

Appleton, K., Mackay, H.J., Judson, I., Plumb, J.A., McCormick, C., Strathdee, G., Lee, C., Barrett, S., Reade, S., Jadayel, D., et al. (2007). Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors, Presented at 17th EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA. JOURNAL OF CLINICAL ONCOLOGY, Vol.25 (29), pp.4603-4609.

Strathdee, G.R., Holyoake, T.L., Sim, A., Parker, A., Oscier, D.G., Melo, J.V., Meyer, S., Eden, T., Dickinson, A.M., Mountford, J., et al. (2007). HOX genes - Candidate tumor suppressor genes in adult, and childhood leukemia., Presented at 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA. BLOOD, Vol.110 (11), p.777A.

Ordway, J.M., Leon, J., Korshunova, Y., Budiman, M.A., Hall, J., Maloney, R.K., Bedell, J.A., Citek, R.W., Jeddeloh, J.A., Brown, R., et al. (2006). New approach for genome wide scanning of differentially methylated genes reveals large list of novel and powerful biomarkers for breast cancer., Presented at 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. BREAST CANCER RESEARCH AND TREATMENT, Vol.100, pp.S43-S44.

White, D.J., Meyer, S., Will, A.M., Sims, A., Eden, T., Brown, R. & Strathdee, G. (2006). No evidence of significant FANCF, FANCB or NBS1 methylation in sporadic acute childhood leukaemia, Presented at 46th Annual Scientific Meetign of the British-Society-for-Haematology, Edinburgh, ENGLAND. BRITISH JOURNAL OF HAEMATOLOGY, Vol.133, p.22.

Plumb, J.A., Aherne, W., Lee, D., Westwood, N., O'Brien, V., McDonald, E. & Brown, R. (2006). MMR201: A novel small molecule that selectively inhibits growth of MLH1 deficient tumor cells, CANCER RESEARCH, Vol.66 (8).

Jansen, R.A., Liu, J.C., Liyanarachchi, S., Crijns, A.P., Van, P.S., Huang, T.H., Cohn, D.E., Fowler, J.M., Van der Zee, A.G. & Brown, R., et al. (2006). Prognostic impact of MAD1L1 promoter hypermethylation in advanced ovarian cancer., Presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Atlanta, GA. JOURNAL OF CLINICAL ONCOLOGY, Vol.24 (18), p.261S.

Lennon, A.M., Tan, A.C., Gleeson, F., Brannigan, A., Lennon, J.R., O'Sullivan, J., White, A., Keegan, D., Mulcahy, H., Hyland, J.M., et al. (2005). Proteomics: A new tool for screening for colon cancer?, Presented at Annual Meeting of the British-Society-of-Gastroenterology, Birmingham, ENGLAND. GUT, Vol.54, p.A20.

Strathdee, G., Holyoake, T.L., Sim, A., Melo, J.V., Soutar, R., Parker, A., Oscier, D.G. & Brown, R. (2005). HoxA cluster genes are frequently targeted by DNA methylation in CML and other types of human leukaemia, Presented at 34th Annual Meeting of the International-Society-for-Experimental-Hematology, Univ Glasgow, Glasgow, SCOTLAND. EXPERIMENTAL HEMATOLOGY, Vol.33 (7), p.50.

Barrett, S.V., Lee, C.P., Appleton, K.J., Reade, S., Jadayel, D., Bellenger, K., Mackay, L.M., Twelves, C.J., Kaye, S.B., Judson, I.R., et al. (2005). Phase I trial of the DNA hypomethylating agent 5-aza-2 ' deoxycytidine (decitabine) in combination with carboplatin both given 4-weekly by intravenous injection in patients with advanced solid tumours., Presented at AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA. CLINICAL CANCER RESEARCH, Vol.11 (24), p.9058S.

Brown, R., Appleton, K., Plumb, J.A., McCormick, C., Lee, C., Barrett, S., Tang, A., Schaetzlein, A., Kaye, S.B., Judson, I., et al. (2005). Pharmacodynamic effects in patients treated with 6 hour infusion of the demethylating agent 5-aza-2 ' deoxycytidine (decitabine)., Presented at AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA. CLINICAL CANCER RESEARCH, Vol.11 (24), pp.9071S-9072S.

Nephew, K.P., Huang, T.T., Wei, S.H., Balch, C. & Brown, R. (2005). Epigenetic regulation of transcription in ovarian cancer., Presented at 38th Annual Meeting of the Society-for-the-Study-of-Reproduction, Ctr Rech Biol Reproduct, Quebec City, CANADA. BIOLOGY OF REPRODUCTION, , pp.79-80.

Hall, J.A., Paul, J., Wei, S.H., Huang, T.H. & Brown, R. (2004). Uncovering complex patterns of CPG island methylation associated with clinical outcome in ovarian cancer, Presented at British Cancer Research Meeting 2004, Manchester, ENGLAND. BRITISH JOURNAL OF CANCER, Vol.91, p.S23.

Teodoridis, J.M., Braidwood, L., Hall, J., Vasey, P.A., Strathdee, G. & Brown, R. (2004). Analysis of aberrant CpG-island methylation in stage III and IV ovarian cancer, Presented at British Cancer Research Meeting 2004, Manchester, ENGLAND. BRITISH JOURNAL OF CANCER, Vol.91, p.S53.

Lee, C., Appleton, K., Plumb, J., Kaye, S., Cruickshank, C., Twelves, C., Vasey, P., Judson, I., Brown, R. & Mackay, H., et al. (2004). A phase I trial of the DNA-hypomethylating agent 5-Aza-2 '-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid turnouts., Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.128S.

Strathdee, G.R., Holyoake, T.L., Sim, A. & Brown, R. (2004). The role of DNA methylation of HoxA5, a regulator of haematopoiesis, in progression to myeloid blast crisis in CML., Presented at 46th Annual Meeting of the American-Society-of-Hematology, San Diego, CA. BLOOD, Vol.104 (11), pp.565A-566A.

Brown, R. (2003). Pharmacodynamics and epigenomics in clinical trials of epigenetic therapies., Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, BOSTON, MASSACHUSETTS. CLINICAL CANCER RESEARCH, Vol.9 (16), p.6275S.

Wei, S.H., Brown, R. & Huang, T.H. (2003). Aberrant DNA methylation in ovarian cancer is there an epigenetic predisposition to drug response?, Presented at Conference on Epigenetic in Cancer Prevention, BETHESDA, MARYLAND. EPIGENETICS IN CANCER PREVENTION: EARLY DETECTION AND RISK ASSESSMENT, Vol.983, pp.243-250.

Brown, R. (1996). Cellular responses to DNA damage and cisplatin resistance, Presented at 1995 HHMT Forum on Ovarian Cancer, GLASGOW, SCOTLAND. OVARIAN CANCER 4, , pp.205-213.